Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dextromethorphan/quinidine - Avanir Pharmaceuticals

X
Drug Profile

Dextromethorphan/quinidine - Avanir Pharmaceuticals

Alternative Names: AVP-923; Dextromethorphan HBr/quinidine sulfate; Dextromethorphan hydrobromide/quinidine sulfate; Neurodex; Nuedexta; Quinidine/dextromethorphan; Zenvia

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Center for Neurologic Study
  • Developer Avanir Pharmaceuticals
  • Class Analgesics; Antimigraines; Antitussives; Behavioural disorder therapies; Cinchona alkaloids; Morphinans; Quinuclidines; Small molecules
  • Mechanism of Action Cytochrome P 450 enzyme system inhibitors; NMDA receptor antagonists; Norepinephrine plasma membrane transport protein inhibitors; Serotonin plasma membrane transport protein inhibitors; Sigma-1 receptor agonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity No

Highest Development Phases

  • Marketed Emotional lability
  • Discontinued Agitation; Diabetic neuropathies; Drug-induced dyskinesia; Migraine; Neuropathic pain

Most Recent Events

  • 14 Feb 2019 Chemical structure information added
  • 27 Nov 2018 No development reported - Phase-II for Agitation in USA (PO)
  • 27 Nov 2018 No development reported - Phase-II for Migraine in USA (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top